Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
A Review on Iron Chelators in Treatment of Iron Overload Syndromes



Mobarra N1 ; Shanaki M2 ; Ehteram H3 ; Nasiri H4 ; Sahmani M5 ; Saeidi M6 ; Goudarzi M7 ; Pourkarim H8 ; Azad M9
Authors
Show Affiliations
Authors Affiliations
  1. 1. Metabolic Disorders Research Center, Department of Biochemistry, School of Medicine, Golestan University of Medical Sciences, Gorgan, Iran
  2. 2. Department of Laboratory Medicine, School of Allied Medical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  3. 3. Department of Pathology, School of Medicine, Kashan University of Medical Sciences, Kashan, Iran
  4. 4. Hematology-Oncology and Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran
  5. 5. Department of Clinical Biochemistry, Cellular and Molecular Research Center, Qazvin University of Medical Sciences, Qazvin, Iran
  6. 6. Stem Cell Research Center, Golestan University of Medical Sciences, Gorgan, Iran
  7. 7. Department of Microbiology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  8. 8. Department of Hematology, Allied Medical School, Tehran University of Medical Sciences, Tehran, Iran
  9. 9. Department of Medical Laboratory Sciences, Faculty of Allied Medicine, Qazvin University of Medical Sciences, Qazvin, Iran

Source: International Journal of Hematology-Oncology and Stem Cell Research Published:2016

Abstract

Iron chelation therapy is used to reduce iron overload development due to its deposition in various organs such as liver and heart after regular transfusion. In this review, different iron chelators implicated in treatment of iron overload in various clinical conditions have been evaluated using more up-to-date studies focusing on these therapeutic agents. Deferoxamine, Deferiprone and Deferasirox are the most important specific US FDA-approved iron chelators. Each of these chelators has their own advantages and disadvantages, various target diseases, levels of deposited iron and clinical symptoms of the afflicted patients which may affect their selection as the best modality. Taken together, in many clinical disorders, choosing a standard chelator does not have an accurate index which requires further clarifications. The aim of this review is to introduce and compare the different iron chelators regarding their advantages and disadvantages, usage dose and specific applications. i¿½ 2016, Tehran University of Medical Sciences (TUMS). All rights reserved.
Related Docs
1. Reproductive Health Issues in Female Patients With Beta-Thalassaemia Major: A Narrative Literature Review, Journal of Obstetrics and Gynaecology (2020)
2. The Association of Pro-Oxidant/Antioxidant Balance and Blood Parameters in Patients With Beta-Thalassemia Major: A Cross-Sectional Study, Blood Research (2023)
3. Apolipoproteins A1, B, and Other Prognostic Biochemical Cardiovascular Risk Factors in Patients With Beta-Thalassemia Major, Hematology (2016)
4. Cost-Utility of New Film-Coated Tablet Formulation of Deferasirox Vs Deferoxamine Among Major Beta-Thalassemia Patients in Iran, Medicine (United States) (2020)
Experts (# of related papers)
View all Related Experts
Maryam Modarres (1)
Zahra Behboodi Moghadam (1)